AnaptysBio, Inc. (ANAB) Analysts See $-0.44 EPS on May, 10

April 17, 2018 - By Jenna Rose

Investors expect AnaptysBio, Inc. (NASDAQ:ANAB)’s quarterly earnings on May, 10., RTT reports. Last year’s earnings per share was $-0.75, while now analysts expect change of 41.33 % up from current $-0.44 earnings per share. Last quarter $-0.30 earnings per share was reported. Analysts forecasts 46.67 % negative EPS growth this quarter. The stock decreased 0.80% or $0.71 during the last trading session, reaching $87.49.AnaptysBio, Inc. has volume of 355,837 shares. Since April 17, 2017 ANAB has risen 290.56% and is uptrending. ANAB outperformed the S&P 500 by 279.01%.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation.The firm is worth $2.08 billion. The company??s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.Currently it has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

AnaptysBio, Inc. (NASDAQ:ANAB) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.